Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Teprotumumab in thyroid eye disease: wonder drug or great divider?

Lookup NU author(s): Dr Petros PerrosORCiD

Downloads

Licence

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).

Abstract

© 2023 the author(s). Progress in the management of thyroid eye disease (TED) has been slow for many decades. The recent introduction of teprotumumab (TEP) in the therapeutic arena for TED has had a major impact in view of its efficacy, particularly with respect to its ability to reduce proptosis. However, the high cost of TEP, limited availability to patients outside the USA, and the lack of data on cost-effectiveness are significant barriers to improving the care of patients with TED globally. Recent guidance from authoritative professional organisations deliver different perspectives on the role of TEP in the routine management of patients with TED, underscoring the complexities of interpreting the evidence. The advance that TEP undoubtedly represents in managing TED effectively has highlighted inequities faced by patients and uncertainties about appropriate metrics of efficacy. Professional organisations have an important role addressing these problems. Future studies need to focus on optimising the measurement of outcomes and on assessing cost-effectiveness.

Publication metadata

Author(s): Perros P, Hegedus L

Publication type: Review

Publication status: Published

Journal: European Thyroid Journal

Year: 2023

Volume: 12

Issue: 4

Online publication date: 12/04/2023

Acceptance date: 11/04/2023

ISSN (print): 2235-0640

ISSN (electronic): 2235-0802

Publisher: BioScientifica Ltd.

URL: https://doi.org/10.1530/ETJ-23-0043

DOI: 10.1530/ETJ-23-0043

Share